tiprankstipranks
Eyepoint Pharma (EYPT)
NASDAQ:EYPT
US Market
EYPT
EyePoint Pharmaceuticals
RESEARCH TOOLSreports
Want to see EYPT full AI Analyst Report?

EyePoint Pharmaceuticals (EYPT) Stock News & Sentiment

1,000 Followers
EyePoint Pharma Bets Big on DURAVYU Pivotal Data
Premium
Company Announcements
EyePoint Pharma Bets Big on DURAVYU Pivotal Data
4d ago
EYPT
EyePoint Advances DURAVYU Phase 3 Wet AMD Program
Premium
Company Announcements
EyePoint Advances DURAVYU Phase 3 Wet AMD Program
10d ago
8K
EYPT
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
Premium
Company Announcements
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
16d ago
EYPT
Yi Chen Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target on DURAVYU Late-Stage Progress
Premium
Ratings
Yi Chen Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target on DURAVYU Late-Stage Progress
17d ago
EYPT
EYPT Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
EYPT Upcoming Earnings Report: What to Expect?
20d ago
EYPT
Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
Premium
Weekend Updates
Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
29d ago
AGX
EYPT
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
Premium
Company Announcements
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
1M ago
8K
EYPT
More EYPT News >

EYPT News on the Web

EyePoint Pharma Bets Big on DURAVYU Pivotal Data
TipRanks News
Neutral
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter | The Motley Fool
Motley Fool
Neutral
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More | The Motley Fool
Motley Fool
Neutral
EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials
TipRanks News
Bullish
EyePoint Advances DURAVYU Phase 3 Wet AMD Program
TipRanks News
Bullish
Mizuho Securities Reaffirms Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
TipRanks News
Bearish
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
TipRanks News
Bullish
RBC Capital Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)
TipRanks News
Bearish

News Score - Last 7 Days

Not enough data to generate a sentiment score
EYPT
Sector Average
Media Buzz
This Week1 articles
Weekly Average4 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is EYPT’s Media Buzz Sentiment?
1 articles about EYPT were published this week. In an average week, 4 articles are published.
    What is EYPT’s weekly average amount of articles?
    In an average week, 4 articles about EYPT are published.
      What is EYPT’s News Sentiment?
      Currently, no data Available
      Healthcare Stocks that are Trending in the News
      GOSSGossamer Bio
      RLAYRelay Therapeutics
      ROIVRoivant Sciences
      ILAIsland Pharmaceuticals Ltd
      TLSATiziana Life Sciences
      Showing the stocks with the most bullish news sentiment over the past week